Increased clearance of morphine in sickle cell disease: implications for pain management. - Wikidata - awgldk - TriplyDB

Increased clearance of morphine in sickle cell disease: implications for pain management.

Increased clearance of morphine in sickle cell disease: implications for pain management.

http://www.wikidata.org/entity/Q34917973

about

Morphine for the treatment of pain in sickle cell disease Treatment of the acute sickle cell vaso-occlusive crisis in the Emergency Department: a Brazilian method of switching from intravenous to oral morphine.Carbon-fiber microelectrode amperometry reveals sickle-cell-induced inflammation and chronic morphine effects on single mast cells Intranasal fentanyl versus intravenous morphine in the emergency department treatment of severe painful sickle cell crises in children: study protocol for a randomised controlled trial.Cytochrome P450 2D6 polymorphisms and predicted opioid metabolism in African American children with sickle cell disease.IMPROVE trial: a randomized controlled trial of patient-controlled analgesia for sickle cell painful episodes: rationale, design challenges, initial experience, and recommendations for future studies Impact of obesity on drug metabolism and elimination in adults and children.Intravenous Lidocaine as an Adjuvant for Pain Associated with Sickle Cell Disease.Tuberculosis in children with sickle cell anaemia: a retrospective study in French tertiary care centres.Pharmacokinetics and analgesic effects of methadone in children and adults with sickle cell disease.Fentanyl Buccal Tablet: A New Breakthrough Pain Medication in Early Management of Severe Vaso-Occlusive Crisis in Sickle Cell Disease.Progressing Preemptive Genotyping of CYP2C19 Allelic Variants for Sickle Cell Disease Patients.Mouse models for studying pain in sickle disease: effects of strain, age, and acuteness.Increased vancomycin dosing requirements in sickle cell disease due to hyperfiltration-dependent and independent pathways.State of the Art Management of Acute Vaso-occlusive Pain in Sickle Cell Disease.Targeting novel mechanisms of pain in sickle cell disease.Treating pain in sickle cell disease with opioids: clinical advances, ethical pitfalls.Population pharmacokinetics of cefotaxime and dosage recommendations in children with sickle cell disease.

P2860

Q28087296-3320151B-A02C-4345-9609-52C86792B6BD Q34406951-81AF8F44-1083-4CA2-AAEF-54E387294688 Q35836675-8B6369D3-6335-4E1B-BC43-1C24899B71AF Q36150411-89DDCBD7-D778-4454-9D68-E3106B0E4EF4 Q37146879-713253FC-8645-41F7-9AC6-AAD8714338FC Q37291510-E9101E8A-FF81-4C01-AAD3-5553C671B57B Q37997025-6656F25A-B894-43BA-B9BC-DD2AE363FCBC Q38665429-DDFC086E-B841-4453-8B78-B1655ABEF9FD Q38841247-F783BF77-730A-49C5-9D88-4B01D4BE682F Q39165843-D12078DA-8B72-4D25-9C91-5FAE30418C59 Q39188770-C90B9D4C-3F99-45BA-BE23-E611C701DC7A Q41642334-C296491E-D2AB-4A4F-AF3B-DF65CFE59795 Q41996084-DE7952E1-EAC3-48FD-9FC9-371D44CBDE97 Q42341701-7929AEB5-7F70-4DB5-AACE-FE82C7E62735 Q43061526-1CC8833D-C16E-4A2E-866C-0E0DD69F720E Q46051242-028EB8BF-4C85-4141-9CFA-46FDED44FC2A Q48070421-F39B4528-3D86-40E8-A93B-7CFC38D1DF80 Q49598847-875E9AC8-7382-43A6-9EC3-1150D33FBB37

P2860

Increased clearance of morphine in sickle cell disease: implications for pain management.

http://www.wikidata.org/entity/Q34917973

description

2011 nî lūn-bûn

@nan

2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Increased clearance of morphine in sickle cell disease: implications for pain management.

@ast

Increased clearance of morphine in sickle cell disease: implications for pain management.

@en

Increased clearance of morphine in sickle cell disease: implications for pain management.

@nl

type

label

Increased clearance of morphine in sickle cell disease: implications for pain management.

@ast

Increased clearance of morphine in sickle cell disease: implications for pain management.

@en

Increased clearance of morphine in sickle cell disease: implications for pain management.

@nl

prefLabel

Increased clearance of morphine in sickle cell disease: implications for pain management.

@ast

Increased clearance of morphine in sickle cell disease: implications for pain management.

@en

Increased clearance of morphine in sickle cell disease: implications for pain management.

@nl

P1433

Q34917973-B5377390-C358-4816-A6C9-C79927386088

P1476

Q34917973-AC2F4879-0638-4E2C-BE69-9A5FE95F73CB

P2093

Q34917973-571BDA0D-301A-4BC0-BB81-34B3E3D75371

Q34917973-8898CA54-71D9-4D25-84B9-2724B813D019

Q34917973-9945CDC4-D4C2-4102-A4FF-90540050B5AC

Q34917973-A5271CAB-767C-4012-89B4-C8F5390E02FE

P2860

Q34917973-137ED050-F723-4540-8A30-64A6F7FF8D3A

Q34917973-157E1B42-0B93-4669-8D9C-E8291692080C

Q34917973-185B06CA-CD8A-46E2-A814-D616C22B6B6C

Q34917973-39707272-C844-4B34-96D8-12C08A6DDB61

Q34917973-4B18BD5C-6233-43F1-BBC6-6D9D7316C4F0

Q34917973-5BC2ED66-4EAD-485D-8262-7D462CA4B2AF

Q34917973-5D15EE36-FABB-4B24-9ECF-E169BD79A00C

Q34917973-5EC0EF36-8D62-4935-AC96-5BAE32ADD342

Q34917973-648138C5-6E75-4A52-86ED-F2DE8D5D2CF2

Q34917973-65323286-5F8C-406F-8C11-4F1D798B19A2

P304

Q34917973-E5AA3561-DD64-4810-9BD1-36751BFFDBCA

P31

Q34917973-174FEF35-E9AD-422E-83A2-B0E268782D6B

P356

Q34917973-5B93956D-137C-44FB-B102-D75E58F5E722

P433

Q34917973-8AE0592E-8D8B-4EE2-9555-0AE147342007

P478

Q34917973-5A7039A3-2DB7-4D01-9780-1B668257E4D2

P577

Q34917973-27B3F348-EB94-4999-94DE-B5D60195DFB1

P5875

Q34917973-CD0A00F0-8F75-4FB1-87D8-CFA7A894336C

P698

Q34917973-2D4F7AB0-59CA-48CB-A8D9-E8969A1DEA61

P921

Q34917973-3E62E2AC-7382-4E9A-AE2D-969827C3E6B4

Q34917973-A05EA209-8211-4E91-AE80-56DB611EE5C6

P932

Q34917973-E8552EF8-C6AB-42F7-A4DC-BD012DB3EA21

P356

J.JPAIN.2010.10.012

P1433

The Journal of Pain

P1476

Increased clearance of morphine in sickle cell disease: implications for pain management.

@en

P2093

Deepika S Darbari

http://www.w3.org/2001/XMLSchema#string

John van den Anker

http://www.w3.org/2001/XMLSchema#string

Michael Neely

http://www.w3.org/2001/XMLSchema#string

Sohail Rana

http://www.w3.org/2001/XMLSchema#string

P2860

The pharmacokinetics of morphine and morphine glucuronides in kidney failure

Morphine and metabolite behavior after different routes of morphine administration: demonstration of the importance of the active metabolite morphine-6-glucuronide

Human UGT2B7 catalyzes morphine glucuronidation

Tolerance and withdrawal from prolonged opioid use in critically ill children.

Ways to fit a PK model with some data below the quantification limit.

Determination of morphine, morphine-3-glucuronide, and morphine-6-glucuronide in plasma after intravenous and intrathecal morphine administration using HPLC with electrospray ionization and tandem mass spectrometry.

Management of sickle cell disease.

Pharmacokinetics of opioids in liver disease.

Glomerular hyperfiltration in adult sickle cell anemia: a frequent hemolysis associated feature

The management of pain in sickle cell disease.

P304

531-538

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.JPAIN.2010.10.012

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P577

2011-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49795181

http://www.w3.org/2001/XMLSchema#string

P698

21277838

http://www.w3.org/2001/XMLSchema#string

P921

sickle-cell disease

pain management

P932

3086992

http://www.w3.org/2001/XMLSchema#string